Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) closed at $47.81 in the latest trading session, marking a -2.35% move from the prior day.
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
EU drugs regulator backs higher dose of Novo's Wegovy
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
Novo Nordisk (NVO) Laps the Stock Market: Here's Why
Novo Nordisk (NVO) closed at $50.29 in the latest trading session, marking a +2.53% move from the prior day.
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap decline stems from a series of adverse events, some justified but many overdone, with the market ignoring positive developments. Despite recent underperformance versus Eli Lilly, NVO maintains industry-leading margins, robust cash flow, and strong growth prospects, notably with oral GLP-1 candidates.
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now trading at a forward P/E of 13.5x, well below historical and sector averages, presenting a de-risked entry point. Zaltenibart targets rare, high-value indications like PNH and complement-mediated nephropathies, offering multi-billion dollar TAM if Phase 3 data prove compelling.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Novo Nordisk Stock Just Hit a 4-Year Low
Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.
Novo Nordisk: Headwinds On The Surface, Deep Value If You Dig
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of 12.66 with robust margins and industry-leading growth, even amid restructuring costs. Recent U.S. drug pricing agreements and Medicare inclusion may pressure short-term sales but are likely to expand long-term market access for NVO's GLP-1 drugs.
